EN DE
Watch BioPorto for free: we tell you when fair value or trend changes.
Data-driven stock valuation

BioPorto (BIOPOR) fair value: what the stock is really worth

As of Nov 11, 2026: fair value (intrinsic value) of BioPorto stock DKK 0.69, price DKK 0.99, that is 30.3% below the price, quality 50 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare DK · ISIN DK0011048619

B BioPorto logo Thin data Nov 10, 2026

BioPorto

BIOPOR · CO
Solid, but expensive

Our calculation puts a fair price 30% below what the stock costs today.

Low debt
Quality 50/100
Mixed Growth (revenue 5y +11.7 %/yr in DKK)
Revenue last quarter 35% below a year ago.
Fair value kr 0.6900 · Overvalued
Loss-making · -46.8% net margin (TTM)
Negative free cash flow
Trails peers (2/9)
Narrow moat 10/100 · thin data
Thin data
Estimate
Watch BioPorto for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 3.85 kr 0.8440 Fair Value kr 0.6900 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range kr 0.8440 – kr 3.85 · fair‑value band kr 0.5200 – kr 0.8700 · the kr 0.9900 price screens above the kr 0.6900 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow BioPorto in your weekly email

Every Wednesday you see whether BioPorto is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

BioPorto A/S, an in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the kidney injury in critically ill patients at earlier stage in Denmark, rest of Europe, North America, and Asia.

Show moreShow less

It offers ProNephro AKI (NGAL), a test for pediatric acute kidney injury (AKI); NGAL Test, a particle-enhanced turbidimetric immunoassay for the quantitative determination of neutrophil gelatinase-associated lipocalin (NGAL) in human urine, EDTA plasma, or heparin plasma on automated clinical chemistry analyzers to diagnose acute kidney injury; and antibodies to develop diagnostic immunoassays within disease areas, including immunodeficiency, allergy, coagulation, diabetes, kidney, and cardiovascular disease.

The company also provides ready-to-use enzyme-linked immunosorbent assay (ELISA) kits to quantify NGAL in urine, plasma, and serum; and generic Rapid Assay Device (gRAD) for custom lateral flow assays. BioPorto A/S was founded in 1917 and is based in Hellerup, Denmark.

Stock analysis

BioPorto (BIOPOR) currently trades at kr 0.9900, while our estimate is kr 0.6900, 30% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: kr 0.5200 (bear) to kr 0.8700 (bull), the price of kr 0.9900 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 50/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

BioPorto reported revenue of 40.3M DKK in FY2025 versus 24.3M DKK in FY2021, a compound +13.5%/yr. Reported net income was −82.1M DKK in FY2025.

Key figures

Market cap 490M DKK (≈ $72.8M) Micro · P/S ratio 13.3 · EPS (TTM) kr −0.0100 · Return on equity −25.7% · Return on assets (EBIT) −78.0% (5-year average) · Operating margin 504% · Revenue (TTM) 38.4M DKK · Revenue growth (YoY) −34.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 28% below its 52-week high and 17% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −11% fair-value upside, at −30%, BIOPOR screens richer than that median.

Fair Value

Bear kr 0.5200 Fair Value kr 0.6900 Bull kr 0.8700
Price kr 0.9900 · Downside -30.3%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 50/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 16
How much profit the company makes from its sales and capital
Quality Growth 40
Are margins and returns getting better?
Cashflow 32
Do the profits arrive as real cash?
Financial strength 84
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 29
How calm the share price moves, does not count
Price momentum 23
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 24
Distance to the 52-week high, does not count
New shares 50
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 31/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+11.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.7%
Start year 2020 (pandemic). Over 10 years: +7.1% a year
Revenue growth 26 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−274.0% (2020) → −213.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

BIOPOR screens overvalued: fair value 30% below the price. Compare with Thermo Fisher Scientific Inc →

Compare BioPorto with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 149 stocks

Beats the industry median on 2/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 50 · Above median
Fair Value upside −30.3% · Below median
Profitability
Return on assets −88.1% · Bottom 25%
Net margin (12 months) −46.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −34.8% · Bottom 25%
Balance sheet
Debt / equity 0.00× · Lowest 25%

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/B 7.78× · Priciest 25%
P/S (12 months) 12.78× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 11
FUTURE (revenue growth)0 · sector 38
PAST (return on equity)0 · sector 7
HEALTH (low debt)100 · sector 95
DIVIDEND (yield)0 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
WuXi AppTec Co 603259 ¥148.70 ¥165.32 +11% vs BIOPOR
Illumina, Inc ILMN $212.93 $236.40 +11% vs BIOPOR
IQVIA Holdings IQV $274.53 $299.58 +9% vs BIOPOR
Thermo Fisher Scientific Inc TMO $717.71 $686.04 −4% vs BIOPOR
Danaher Corporation DHR $235.31 $209.18 −11% vs BIOPOR
IDEXX Laboratories, Inc IDXX $702.59 $496.48 −29% vs BIOPOR
Lonza Group LONN CHF 663.60 CHF 259.80 −61% vs BIOPOR
Mettler-Toledo International Inc MTD $1,749 $655.06 −63% vs BIOPOR
Agilent Technologies, Inc A $176.95 $64.53 −64% vs BIOPOR
Waters Corporation WAT $470.90 $91.26 −81% vs BIOPOR

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Average Down CalculatorFree calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

BioPorto: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "BioPorto Fair Value". https://www.fairvalue-calculator.com/stock/BIOPOR

Frequently asked questions

Is BioPorto (BIOPOR) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is kr 0.6900 versus a price of kr 0.9900, about 30% lower (overvalued).
What is the fair value of BIOPOR?
Our estimate for BioPorto is kr 0.6900 (as of Nov 10, 2026), built from audited fundamentals. The current price: kr 0.9900.
What is the quality score of BIOPOR?
BioPorto has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for BioPorto (BIOPOR)?
Our calculated price target is the estimate of kr 0.6900 (as of Nov 10, 2026). Cautious scenario kr 0.5200, optimistic scenario kr 0.8700. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the BioPorto stock forecast for 2026?
Our estimate puts fair value at kr 0.6900, about 30% lower versus a price of kr 0.9900 (overvalued). Cautious scenario kr 0.5200, optimistic scenario kr 0.8700. The calculation is refreshed regularly with new filings.
What is the revenue of BioPorto (BIOPOR)?
BioPorto reported trailing-twelve-month revenue of about 38.4M DKK (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of BioPorto (BIOPOR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BioPorto it is kr 0.6900 per share (as of Nov 10, 2026), against a price of kr 0.9900.
Is BioPorto stock overvalued or undervalued in 2026?
As of Nov 10, 2026, BIOPOR trades above its calculated fair value: price kr 0.9900, fair value kr 0.6900, a gap of about −30% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BIOPOR?
No. The price is what the market pays today (kr 0.9900); the fair value is what the company's own numbers justify (kr 0.6900). For BioPorto the two are kr 0.3000 per share apart. That gap is exactly why we show both numbers side by side.
How much is BioPorto worth?
The market values BioPorto at about 490M DKK (market capitalisation, as of Nov 10, 2026). Per share that is kr 0.9900; our models calculate a fair value of kr 0.6900 per share.
What do the bullish and bearish scenarios say about BIOPOR?
Our models span a range for BioPorto: cautious scenario kr 0.5200, base kr 0.6900, optimistic kr 0.8700 per share (as of Nov 10, 2026, price kr 0.9900). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of BioPorto (BIOPOR)?
Balance-sheet figures for BioPorto (as of Nov 10, 2026): return on equity −25.7%, debt of 0.00 per unit of equity. They feed the Quality Score of 50/100, which measures business quality independently of the share price.
How far is BIOPOR from its 52-week high?
BioPorto trades at kr 0.9900, about 28% below its 52-week high of kr 1.37 and 17% above the low of kr 0.8440 (as of Nov 11, 2026). Distance from the high says nothing about value: that is what the fair value of kr 0.6900 is for.
Which stocks are comparable to BioPorto?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, IDEXX Laboratories, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is BioPorto stock attractive at the current price?
The data as of Nov 10, 2026: price kr 0.9900, calculated fair value kr 0.6900 (−30%), Quality Score 50/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0% above its aggregate fair value. BioPorto itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of BioPorto (BIOPOR)?
The closing price on Nov 11, 2026 was kr 0.9900. Our estimate is kr 0.6900, about 30% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with BioPorto right now?
The price sits above even our optimistic bull case (kr 0.8700). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (50/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of BioPorto

How large is the market capitalisation of BioPorto (BIOPOR)?
The market capitalisation of BioPorto is 490M DKK (≈ $72.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of BioPorto (BIOPOR)?
The price-to-sales ratio of BioPorto is 13.3 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of BioPorto (BIOPOR)?
Earnings per share at BioPorto are kr −0.0100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of BioPorto (BIOPOR)?
The return on equity (ROE) of BioPorto is −25.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of BioPorto (BIOPOR)?
On an EBIT basis the return on assets of BioPorto is −78.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of BioPorto (BIOPOR)?
The operating margin of BioPorto is 504% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at BioPorto (BIOPOR)?
Revenue at BioPorto is growing −34.8% versus a year earlier (3y avg +11.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does BioPorto (BIOPOR) generate?
The free cash flow of BioPorto is −77.1M DKK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does BioPorto (BIOPOR) hold?
BioPorto holds more cash than debt, 47.4M DKK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch BioPorto in the live analysis

One click puts BioPorto on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.